Skip to main content

New Progress in the Treatment of Bone and Soft Tissue Tumors

56kviews
Editorial23 May 2024
Editorial: New progress in the treatment of bone and soft tissue tumors
Duoyi Zhao, Jiachen Yu, Chengbin Ma, Xiaoyu Xuand Zhiyu Zhang

Bone and soft tissue tumors, constitute a heterogeneous group of neoplasms that frequently affect the young. These tumors are highly aggressive, often metastasizing early in the disease's progression, posing a significant challenge to orthopedic oncologists. Treatment strategies for these tumors have evolved, with a mainstay approach combining surgery, chemotherapy, and more recently, the introduction of targeted therapies and immunotherapy. Over the past decade, there have been significant advancements in the molecular understanding of these tumors, leading to the development of innovative therapeutic strategies that hold promise for improving patient outcomes and potentially modifying the prognosis of these malignancies.This study encompassed a total of 10 articles, comprising 4 original research articles, 5 review articles, and 1 case report.

RNA PRR7-AS1 in the development of bone sarcoma and evaluated its potential as a therapeutic target. The team discovered that PRR7-AS1 interacts with the protein RNF2, thereby inhibiting the translation of the downstream gene MTUS1, which in turn promotes the proliferation and migration of bone sarcoma cells. Furthermore, the researchers found that the knockdown of PRR7-AS1 significantly suppressed the in vitro proliferation and the in vivo growth and metastasis of bone sarcoma cells. These findings underscore the oncogenic role of PRR7-AS1 in bone sarcoma and suggest its potential as a novel target for diagnosis and treatment.

that was inoperable and successfully treated with Denosumab. The case involved a 49year-old male who had undergone two surgeries for GCTB in the right proximal ulna.A CT-guided needle biopsy revealed rapid growth and high 18F-FDG uptake, though no histological signs of malignancy were present. Given that the lung lesion was not surgically removable, Denosumab was administered. After 18 months of initial treatment with Denosumab, there were no symptoms or signs of tumor growth. While the long-term efficacy and safety of Denosumab remain to be determined, the authors posit that it may represent a viable treatment option for patients with non-resectable pulmonary GCTB. Osumi and colleagues' study on the role of proteoglycan synthesis genes in osteosarcoma stem cells offers valuable insights into cellular mechanisms that could be targeted for therapy. Understanding the pathways that govern the self-renewal and differentiation of osteosarcoma stem cells is essential for developing targeted therapies to effectively counteract tumor recurrence and metastasis. These therapies are designed to disrupt specific molecular pathways driving tumor growth, offering a more personalized approach to treatment.

1,702 views

The rich blood supply of the bone marrow provides favorable conditions for tumor cell proliferation and growth. In the disease's early stages, circulating tumor cells can escape to the bone marrow and form imperceptible micro metastases. These tumor cells may be reactivated to regain the ability to grow aggressively and eventually develop into visible metastases. Symptomatic bone marrow metastases with abnormal hematopoiesis solid tumor metastases are rare and have poor prognoses. Treatment options are carefully chosen because of the suppression of bone marrow function. In this review, we summarized the mechanisms involved in developing bone marrow metastases from tumor cells and the clinical features, treatment options, and prognosis of patients with symptomatic bone marrow metastases from different solid tumors reported in the literature.

8,807 views

14 citations

Hypoxia inducible factor-1ɑ as a potential therapeutic target for osteosarcoma metastasis
REVIEW
24 January 2024
Hypoxia inducible factor-1ɑ as a potential therapeutic target for osteosarcoma metastasis
Jianghu Zhou, 5 more and Hong Sun
Osteosarcoma (OS) is a malignant tumor originating from mesenchymal tissue.Pulmonary metastasis is usually present upon initial diagnosis, and metastasis is the primary factor affecting the poor prognosis of patients with OS. Current research shows that the ability to regulate the cellular microenvironment is essential for preventing the distant metastasis of OS, and anoxic microenvironments are important features of solid tumors. During hypoxia, hypoxia-inducible factor-1α (HIF-1α) expression levels and stability increase. Increased HIF-1α promotes tumor vascular remodeling, epithelial-mesenchymal transformation (EMT), and OS cells invasiveness; this leads to distant metastasis of OS cells. HIF-1α plays an essential role in the mechanisms of OS metastasis. In order to develop precise prognostic indicators and potential therapeutic targets for OS treatment, this review examines the molecular mechanisms of HIF-1α in the distant metastasis of OS cells; the signal transduction pathways mediated by HIF-1α are also discussed.

5,050 views

29 citations

5,478 views

11 citations

ORIGINAL RESEARCH
6 December 2023
Pre- and post-chemotherapy spermatogenesis in male patients with malignant bone and soft tissue tumors
Teppei Takeshima, 7 more and Yasushi Yumura

2,713 views

4 citations

ORIGINAL RESEARCH
16 November 2023
Long non-coding RNA PRR7-AS1 promotes osteosarcoma progression via binding RNF2 to transcriptionally suppress MTUS1
Gu Chen-Xi, 7 more and Shen Jun

3,226 views

1 citations

Potential targets and applications of nanodrug targeting myeloid cells in osteosarcoma for the enhancement of immunotherapy
Targeted immunotherapies have emerged as a transformative approach in cancer treatment, offering enhanced specificity to tumor cells, and minimizing damage to healthy tissues. The targeted treatment of the tumor immune system has become clinically applicable, demonstrating significant anti-tumor activity in both early and late-stage malignancies, subsequently enhancing long-term survival rates. The most frequent and significant targeted therapies for the tumor immune system are executed through the utilization of checkpoint inhibitor antibodies and chimeric antigen receptor T cell treatment. However, when using immunotherapeutic drugs or combined treatments for solid tumors like osteosarcoma, challenges arise due to limited efficacy or the induction of severe cytotoxicity. Utilizing nanoparticle drug delivery systems to target tumor-associated macrophages and bone marrow-derived suppressor cells is a promising and attractive immunotherapeutic approach. This is because these bone marrow cells often exert immunosuppressive effects in the tumor microenvironment, promoting tumor progression, metastasis, and the development of drug resistance.Moreover, given the propensity of myeloid cells to engulf nanoparticles and microparticles, they are logical therapeutic targets. Therefore, we have discussed the mechanisms of nanomedicine-based enhancement of immune therapy through targeting myeloid cells in osteosarcoma, and how the related therapeutic strategies well adapt to immunotherapy from perspectives such as promoting immunogenic cell death with nanoparticles, regulating the proportion of various cellular subgroups in tumor-associated macrophages, interaction with myeloid cell receptor ligands, activating Running Title 2 immunostimulatory signaling pathways, altering myeloid cell epigenetics, and modulating the intensity of immunostimulation. We also explored the clinical implementations of immunotherapy grounded on nanomedicine.

4,095 views

13 citations

ORIGINAL RESEARCH
17 August 2023
A novel poly(3-hydroxybutyrate-co-3-hydroxyvalerate) (PHBV)-PEG-melatonin composite scaffold enhances for inhibiting bone tumor recurrence and enhancing bone regeneration
Wei-Lin Zhang, 4 more and Jin-Song Wei

2,425 views

7 citations